# Deep Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/deep-bio

- Industry: Healthcare IT
- Headquarters: Seoul, South Korea
- Website: www.deepbio.co.kr
- Total disclosed funding: $13M
- Latest round: Series B (Jun 5, 2020)
- Investors on record: 10

## About

Based in South Korea, Deep Bio Inc. specializes in artificial intelligence-driven diagnostics for cancer, focusing on improving accuracy in pathology assessments.Deep Bio Inc. is a healthcare technology firm established in 2015 in Seoul, South Korea, aimed at enhancing cancer diagnostics. The company has successfully closed 6 deals, with its most recent funding round occurring in November 2023. The founder, Sun-woo Kim, also serves as the CEO. Deep Bio has raised a total of KRW 2.3 billion from investors including Cheil Electric, DB Financial Investment, and The Wells Investment, leading to a current company valuation of KRW 81,527.793 million.Deep Bio specializes in artificial intelligence-driven solutions for cancer diagnostics, primarily offering its flagship product, the DeepDx® suite. This suite includes applications such as DeepDx® Prostate, designed for the detection and diagnosis of prostate cancer through advanced image analysis techniques. Leveraging deep learning algorithms, DeepDx® enhances the accuracy of pathology assessments, assisting medical professionals in making informed treatment decisions. The platform is utilized by healthcare facilities globally, including in South Korea, Europe, and the United States, focusing on optimizing tumor analysis and improving diagnostic precision.In 2023, Deep Bio generated revenue amounting to KRW 300,931.7 million. The company reported an EBITDA loss of KRW 2,868,365.6 million for the same year.Following its latest funding round in November 2023, where Deep Bio Inc. raised KRW 2.3 billion, the company plans to enhance its product offerings and expand into new geographic markets. Investments will focus on developing additional AI-driven diagnostic tools, aiming for release by the end of 2024. Deep Bio is targeting further expansion in North America and Europe, leveraging the recent capital to support these initiatives and strengthen its market presence.

## Funding rounds

- Series B, Jun 5, 2020, $1.6M — NH Investment & Securities
- Series B, Mar 10, 2020, $9.9M — Hyundai Venture Investment, Shinhan Venture Investment, Partners Investment, G.N.TECH Venture Capital, Albatross Investment, Daekyo Investment, DT&Investment, Maple Investment Partners, Sneak Peek Investment
- Series A, Apr 21, 2017, $1.3M — Shinhan Venture Investment

## Investors

- Shinhan Venture Investment (https://capitalatlas.ai/funds/shinhan-venture-investment) — Series A, Series B
- Hyundai Venture Investment (https://capitalatlas.ai/funds/hyundai-venture-investment) — Series B
- Partners Investment (https://capitalatlas.ai/funds/partners-investment) — Series B
- G.N.TECH Venture Capital (https://capitalatlas.ai/funds/g-n-tech-venture-capital) — Series B
- Albatross Investment (https://capitalatlas.ai/funds/albatross-investment) — Series B
- Daekyo Investment (https://capitalatlas.ai/funds/daekyo-investment) — Series B
- DT&Investment (https://capitalatlas.ai/funds/dt-investment) — Series B
- Maple Investment Partners (https://capitalatlas.ai/funds/maple-investment-partners) — Series B
- Sneak Peek Investment (https://capitalatlas.ai/funds/sneak-peek-investment) — Series B
- NH Investment & Securities (https://capitalatlas.ai/funds/nh-investment-securities) — Series B